Trial Profile
A pivotal study of oral rigosertib in patients with lower risk myelodysplastic syndromes (MDS)
Status:
Planning
Phase of Trial:
Phase III
Latest Information Update: 19 Apr 2024
Price :
$35
*
At a glance
- Drugs Rigosertib (Primary)
- Indications Myelodysplastic syndromes
- Focus Therapeutic Use
- 02 Apr 2024 According to a Onconova Therapeutics media release, Trawsfynydd Therapeutics has merged with Onconova Therapeutics to form Traws Pharma
- 15 Oct 2014 New trial record